CYTK Covered Call Strategy
CYTK (Cytokinetics, Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK (Cytokinetics, Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $10.23B, a beta of 0.44 versus the broader market, a 52-week range of 32.66-84.55, average daily share volume of 2.5M, a public-listing history dating back to 2004, approximately 673 full-time employees. These structural characteristics shape how CYTK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.44 indicates CYTK has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a covered call on CYTK?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current CYTK snapshot
As of June 30, 2026, spot at $85.53, ATM IV 39.70%, IV rank 0.67%, expected move 11.38%. The covered call on CYTK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this covered call structure on CYTK specifically: CYTK IV at 39.70% is on the cheap side of its 1-year range, which means a premium-selling CYTK covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 11.38% (roughly $9.73 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CYTK expiries trade a higher absolute premium for lower per-day decay. Position sizing on CYTK should anchor to the underlying notional of $85.53 per share and to the trader's directional view on CYTK stock.
CYTK covered call setup
The CYTK covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CYTK near $85.53, the first option leg uses a $90.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CYTK chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CYTK shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $85.53 | long |
| Sell 1 | Call | $90.00 | $1.55 |
CYTK covered call risk and reward
- Net Premium / Debit
- -$8,398.00
- Max Profit (per contract)
- $602.00
- Max Loss (per contract)
- -$8,397.00
- Breakeven(s)
- $83.98
- Risk / Reward Ratio
- 0.072
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
CYTK covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on CYTK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$8,397.00 |
| $18.92 | -77.9% | -$6,505.99 |
| $37.83 | -55.8% | -$4,614.99 |
| $56.74 | -33.7% | -$2,723.98 |
| $75.65 | -11.6% | -$832.98 |
| $94.56 | +10.6% | +$602.00 |
| $113.47 | +32.7% | +$602.00 |
| $132.38 | +54.8% | +$602.00 |
| $151.29 | +76.9% | +$602.00 |
| $170.20 | +99.0% | +$602.00 |
When traders use covered call on CYTK
Covered calls on CYTK are an income strategy run on existing CYTK stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
CYTK thesis for this covered call
The market-implied 1-standard-deviation range for CYTK extends from approximately $75.80 on the downside to $95.26 on the upside. A CYTK covered call collects premium on an existing long CYTK position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether CYTK will breach that level within the expiration window. Current CYTK IV rank near 0.67% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CYTK at 39.70%. As a Healthcare name, CYTK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CYTK-specific events.
CYTK covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CYTK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CYTK alongside the broader basket even when CYTK-specific fundamentals are unchanged. Short-premium structures like a covered call on CYTK carry tail risk when realized volatility exceeds the implied move; review historical CYTK earnings reactions and macro stress periods before sizing. Always rebuild the position from current CYTK chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on CYTK?
- A covered call on CYTK is the covered call strategy applied to CYTK (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With CYTK stock trading near $85.53, the strikes shown on this page are snapped to the nearest listed CYTK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CYTK covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the CYTK covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 39.70%), the computed maximum profit is $602.00 per contract and the computed maximum loss is -$8,397.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CYTK covered call?
- The breakeven for the CYTK covered call priced on this page is roughly $83.98 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CYTK market-implied 1-standard-deviation expected move is approximately 11.38%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on CYTK?
- Covered calls on CYTK are an income strategy run on existing CYTK stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current CYTK implied volatility affect this covered call?
- CYTK ATM IV is at 39.70% with IV rank near 0.67%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.